The stock has been favored amongst insiders Stephen Hoffman, director at Dicerna Pharmaceuticals Inc (NASDAQ : DRNA), purchased 200,000 shares from the IPO, and currently owns around 1.73 million shares. RA Capital Management invests in companies with promising drugs and technologies. A day before the fund revealed in a filing that it initiated a stake in Furiex Pharmaceuticals Inc (NASDAQ : FURX ), and now holds 750,000 shares. At the end of September 2013, RA Capital Management held 10.42 million shares of Dyax Corp. (NASDAQ : DYAX ), with 7.45% of its equity portfolio invested in the company's stock. Disclosure: none Recommended Reading: Diamond Hill Capital Management Top Picks: United Technologies Corp. (UTX), American International Group Inc. (AIG) & More Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO) Hedge Fund Highlights: Warren Buffett, Bill Ackman & Richard Gerson